Phase l Study of RMC-6236 in Patients with Advanced Solid Tumors, including Pancreatic Cancer Tumors Harboring Specific Mutations in KRAS
Summary
The purpose of this study is to evaluate the safety and feasibility of RMC- 6236 in adults with KRAS p.G12 mutant advanced solid tumors, including pancreatic cancer.
General Information
NCT#: NCT05379985
Study ID: RMC-6236-001
Trial Phase: Phase I
Trial Sponsor: Revolution Medicines, Inc.
Therapies Used in This Trial: RMC- 6236